TY - JOUR AU - Holzer, Philipp PY - 2017/10/25 Y2 - 2024/03/28 TI - Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs JF - CHIMIA JA - Chimia VL - 71 IS - 10 SE - Scientific Articles DO - 10.2533/chimia.2017.716 UR - https://www.chimia.ch/chimia/article/view/2017_716 SP - 716 AB - As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs. ER -